Abstract
Introduction: Some severe hemophiliacs (FVIII/FIX<1%) exhibit a mild bleeding tendency, but the basis for this clinical heterogeneity is poorly understood. This study investigated the relationship between the values of endogenous thrombin potential (ETP) and clinical phenotype in severe hemophiliacs. The impact of FVIII/FIX gene mutations and thrombophilic polymorphisms was also evaluated. Methods: severe hemophiliacs older than 18 years without inhibitor history and treated on demand were eligible. Mild bleeders (MB) and severe bleeders (SB) were defined as follows: spontaneous bleeding episodes per year ≤2 (MB) or 25 (SB) and concentrate consumption <500 (MB) or >2000 (SB) IU/Kg/year. Patients who did not fit these criteria were considered as intermediate bleeders (IB). FVIII was measured by chromogenic assay and ETP was measured in platelet-rich plasma after addition of tissue factor. Results: 22MB, 22SB and 28IB were enrolled. MB had lower clinical and radiological scores when compared with both IB and SB (p<0.005). MB showed an older age at first bleed compared to SB (p < 0.005) and p for trend among the 3 groups was also significant (p < 0.05). The prevalence of severe FVIII/FIX gene defects (null mutations) was lower and ETP values were higher in MB compared with both IB and SB (p<0.05; table 1). Conclusions: our results indicate an extremely low prevalence of null mutations in severe hemophiliacs with mild bleeding diathesis. The measurement of thrombin generation in platelet-rich plasma may allow to identify this subgroup of patients, not otherwise distinguishable by conventional functional assays.
. | SB (#22) . | IB (#28) . | MB (#22) . | p . |
---|---|---|---|---|
Age (yr) | 38 (21–76) | 38 (23–62) | 32 (22–73) | NS |
Age 1st bleed (yr) | 1 (0–4) | 2 (0–6) | 3 (1–10) | < 0.005 |
Bleeding episodes/yr | 36 (25–60) | 10 (3–20) | 0 (0–2) | < 0.0005 |
Factor use (IU/Kg/yr) | 2207 (2040–8696) | 1068 (207–2400) | 60 (25–487) | < 0.0005 |
Clinical score | 18 (10–35) | 10 (0–34) | 3 (0–17) | < 0.005 |
Pettersson score | 44 (14–62) | 28 (0–48) | 17 (3–40) | < 0.0005 |
Null mutations (%) | 59 | 70 | 6 | < 0.005 |
PTG20210A (%) | 0 | 7 | 5 | NS |
FV Leiden (%) | 5 | 7 | 0 | NS |
Median ETP (nM) | 414 | 478 | 850 | < 0.05 |
. | SB (#22) . | IB (#28) . | MB (#22) . | p . |
---|---|---|---|---|
Age (yr) | 38 (21–76) | 38 (23–62) | 32 (22–73) | NS |
Age 1st bleed (yr) | 1 (0–4) | 2 (0–6) | 3 (1–10) | < 0.005 |
Bleeding episodes/yr | 36 (25–60) | 10 (3–20) | 0 (0–2) | < 0.0005 |
Factor use (IU/Kg/yr) | 2207 (2040–8696) | 1068 (207–2400) | 60 (25–487) | < 0.0005 |
Clinical score | 18 (10–35) | 10 (0–34) | 3 (0–17) | < 0.005 |
Pettersson score | 44 (14–62) | 28 (0–48) | 17 (3–40) | < 0.0005 |
Null mutations (%) | 59 | 70 | 6 | < 0.005 |
PTG20210A (%) | 0 | 7 | 5 | NS |
FV Leiden (%) | 5 | 7 | 0 | NS |
Median ETP (nM) | 414 | 478 | 850 | < 0.05 |
Disclosures: No relevant conflicts of interest to declare.
Author notes
Corresponding author
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal